Translational Biology Lab

Evidence should change the decision.

Adjust genetics, mechanism, cellular context, biomarkers and safety. The recommendation is deliberately revisable: the goal is to expose uncertainty and identify the next experiment with the highest decision value.

Evidence-to-decision exercise

Make the reasoning explicit.

This is a research-programme simulation, not a clinical recommendation. It teaches how heterogeneous evidence can support GO, PAUSE, REDIRECT or STOP while remaining open to revision.

Human genetics 65

Mechanistic validation 70

Cellular / tissue context 55

Biomarker readiness 40

Safety / redundancy confidence 50

Research-programme decision simulation

PAUSE

Evidence is promising but a decision-critical gap remains.

Highest-value next experimentStrengthen biomarker readiness

The weakest evidence layer currently limits confidence more than the stronger layers add it.

Worked example · published mechanismALC1 auto-inhibition and PARP-dependent activation

The 2017 single-first-author Molecular Cell study defined how poly-ADP-ribose releases ALC1 auto-inhibition, joining DNA-damage signalling, chromatin remodelling and oncology. That published mechanism forms part of the scientific lineage of later ALC1-focused therapeutic development — a real instance of the evidence-to-decision path this exercise models. Open the Molecular Cell study ↗

Principle: translation is the disciplined conversion of heterogeneous evidence into revisable decisions—not a single score pretending uncertainty has disappeared.